This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cyclacel Pharmaceuticals, Inc.
Drug Names(s): CYC682
Description: Sapacitabine (CYC682) is an orally available 2'-deoxycytidine nucleoside analog. Nucleoside drugs work by inhibiting DNA synthesis. A number of nucleoside drugs, such as gemcitabine, are in widespread use as conventional chemotherapies.
Deal Structure: Sapacitabine was originally developed by Daiichi Sankyo.
In December 2003, Cyclacel and Sankyo announced that Cyclacel acquired exclusive rights in nearly all world territories to a Sankyo anticancer drug code-named CYC682.
Sankyo received an upfront payment and will receive milestones and royalties from Cyclacel. In addition, Sankyo has retained a right of first negotiation to market the compound in Japan. Specific financial terms were not disclosed.
In July 2011, Cyclacel announced that it had entered into an amendment of its license agreement between Cyclacel and Daiichi Sankyo relating to certain rights which Cyclacel has licensed from Daiichi Sankyo with regard to the Companys sapacitabine drug.
Pursuant to the amendment, Daiichi Sankyo irrevocably waived a termination right it possessed under a provision of the License Agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least one country by September 2011, and has released...See full deal structure in Biomedtracker
Partners: Daiichi Sankyo Co., Ltd.
Additional information available to subscribers only: